Das Avinaba, Gowda B H Jaswanth, Hani Umme, Paul Karthika, Ahmed Mohammed Gulzar, Abdi Gholamreza, Shimu Sharmin Sultana
Department of Pharmaceutics, Yenepoya Pharmacy College & Research Centre, Yenepoya (Deemed to be University), Mangalore 575018, Karnataka, India.
Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 61421, Saudi Arabia.
Curr Pharm Des. 2025;31(23):1823-1843. doi: 10.2174/0113816128337166241219081400.
Cardiovascular diseases (CVDs) remain a global health challenge, with hypertension emerging as a leading risk factor. Hypertension, characterized by elevated arterial blood pressure (BP), significantly increases the risk of stroke and other CVDs. Despite advancements in antihypertensive medication, the effectiveness of hypertension treatment is often hindered by poor bioavailability and limited drug efficacy. In this quest, nanoparticles (NPs) offer a promising avenue for addressing the limitations associated with conventional antihypertensive drugs in hypertension treatment. Among several NPs, solid lipid nanoparticles (SLNs) have emerged as a potential candidate, presenting a multifaceted approach to revolutionize drug delivery within this domain. SLNs, characterized by a lipophilic matrix and stabilized by surfactants, offer scalability and compatibility with biological systems compared to several polymer-based nanosystems. By encapsulating antihypertensive drugs, SLNs enhance drug solubility and bioavailability and provide sustained release, thereby improving treatment efficacy. In this context, this review provides an overview of the pathophysiology of hypertension and the role of SLNs in drug delivery. Various preparation techniques of SLNs are discussed, highlighting their versatility and potential in pharmaceutical applications. Furthermore, the role of SLNs in the management of hypertension is thoroughly examined, with a focus on enhancing the physicochemical properties of antihypertensive drugs. Overall, SLNs represent a promising strategy for optimizing hypertension treatment by addressing the limitations of conventional drug delivery systems. By enhancing drug stability, bioavailability, and efficacy, SLNs offer new possibilities for improving patient outcomes and reducing the global burden of cardiovascular diseases. This review aims to contribute to the ongoing research and development of innovative therapies for hypertension management.
心血管疾病(CVDs)仍然是一项全球性的健康挑战,高血压已成为主要的风险因素。高血压以动脉血压(BP)升高为特征,显著增加了中风和其他心血管疾病的风险。尽管抗高血压药物取得了进展,但高血压治疗的有效性常常受到生物利用度差和药物疗效有限的阻碍。在这一探索过程中,纳米颗粒(NPs)为解决传统抗高血压药物在高血压治疗中存在的局限性提供了一条有前景的途径。在几种纳米颗粒中,固体脂质纳米粒(SLNs)已成为一种潜在的候选者,呈现出一种多方面的方法来革新该领域内的药物递送。与几种基于聚合物的纳米系统相比,固体脂质纳米粒以亲脂性基质为特征,并由表面活性剂稳定,具有可扩展性且与生物系统兼容。通过包裹抗高血压药物,固体脂质纳米粒提高了药物的溶解度和生物利用度,并提供持续释放,从而提高治疗效果。在此背景下,本综述概述了高血压的病理生理学以及固体脂质纳米粒在药物递送中的作用。讨论了固体脂质纳米粒的各种制备技术,突出了它们在药物应用中的多功能性和潜力。此外,还深入研究了固体脂质纳米粒在高血压管理中的作用,重点是增强抗高血压药物的物理化学性质。总体而言,固体脂质纳米粒通过解决传统药物递送系统的局限性,代表了一种优化高血压治疗的有前景的策略。通过提高药物稳定性、生物利用度和疗效,固体脂质纳米粒为改善患者预后和减轻全球心血管疾病负担提供了新的可能性。本综述旨在为高血压管理创新疗法的持续研究和开发做出贡献。